Saved in:
| Main Author: | |
|---|---|
| Format: | Recurso digital |
| Language: | |
| Published: |
Zenodo
2026
|
| Subjects: | |
| Online Access: | https://doi.org/10.5281/zenodo.18224340 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866901501754998784 |
|---|---|
| author | Phupu Tshering Bhutia, Balakeswa Ramaiah, Sonam Yangchen Bhutia |
| author_facet | Phupu Tshering Bhutia, Balakeswa Ramaiah, Sonam Yangchen Bhutia |
| contents | <p><span lang="EN-US">Background: Noradrenaline is a high-risk medication used to regulate blood pressure as a vasopressor. The dosing strategy plays a crucial role in managing blood pressure, MAP, and heart rate, but needs close monitoring to reduce some of its adverse events in critical care. Materials and methods: Patients admitted to the ICU, HICU, or CCU diagnosed with shock and treated with noradrenaline were included in this study. Three-time points were selected: T1 (the first hour of norepinephrine infusion), T24 (the 24 hours that followed T1), and T peak (the maximal dose taken during the first 24 hours of treatment). The Blood pressure, heart rate, MAP, and dose were assessed based on these three time points to determine the impact of noradrenaline. Several laboratory parameters were considered before and after noradrenaline.<span> </span>Results: A total of 70 patients were included in the study, most of whom were male, primarily aged between middle and old. Septic shock was the most common indication for noradrenaline. The maximum number of days Norad used was 12. However, in a higher number of patients, it was used for 3 days. Noradrenaline significantly increased systolic blood pressure from 87.73 ± 17.06 mmHg at baseline (T0) to 108.36 ± 21.34 mmHg at 1 hour (T1), remaining stable at 107.55 ± 22.96 mmHg (T24) and rising to 115.39 ± 24.51 mmHg post-discontinuation. Similarly, the DBP increased from 53.84 ± 12.85 mmHg at T0 to 66.18 ± 12.85 mmHg at T1 and a slight decrease at 24 hours. Although there was a decline in heart rate at 102 from baseline to 87 bpm after treatment. A total of 59 drug interactions were found with various drugs, most of which were seen with furosemide. Conclusion: In this study of 70 patients under noradrenaline therapy, varied patterns of outcomes and results were noted. 34% were transferred to the ward, and 30% were also successfully discharged. The mortality rate of 25.1% shows that there is room for improvement in the treatment regimen. Although the dosing strategy in managing BP, MAP and HR were seen to be effective, there is room for development.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_18224340 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Noradrenaline Utilisation and Hemodynamic Trends in Critically Ill Patients: An Observational Study from a Tertiary Care Hospital Phupu Tshering Bhutia, Balakeswa Ramaiah, Sonam Yangchen Bhutia Noradrenaline, shock, critical care, vasopressor therapy, Mean arterial pressure <p><span lang="EN-US">Background: Noradrenaline is a high-risk medication used to regulate blood pressure as a vasopressor. The dosing strategy plays a crucial role in managing blood pressure, MAP, and heart rate, but needs close monitoring to reduce some of its adverse events in critical care. Materials and methods: Patients admitted to the ICU, HICU, or CCU diagnosed with shock and treated with noradrenaline were included in this study. Three-time points were selected: T1 (the first hour of norepinephrine infusion), T24 (the 24 hours that followed T1), and T peak (the maximal dose taken during the first 24 hours of treatment). The Blood pressure, heart rate, MAP, and dose were assessed based on these three time points to determine the impact of noradrenaline. Several laboratory parameters were considered before and after noradrenaline.<span> </span>Results: A total of 70 patients were included in the study, most of whom were male, primarily aged between middle and old. Septic shock was the most common indication for noradrenaline. The maximum number of days Norad used was 12. However, in a higher number of patients, it was used for 3 days. Noradrenaline significantly increased systolic blood pressure from 87.73 ± 17.06 mmHg at baseline (T0) to 108.36 ± 21.34 mmHg at 1 hour (T1), remaining stable at 107.55 ± 22.96 mmHg (T24) and rising to 115.39 ± 24.51 mmHg post-discontinuation. Similarly, the DBP increased from 53.84 ± 12.85 mmHg at T0 to 66.18 ± 12.85 mmHg at T1 and a slight decrease at 24 hours. Although there was a decline in heart rate at 102 from baseline to 87 bpm after treatment. A total of 59 drug interactions were found with various drugs, most of which were seen with furosemide. Conclusion: In this study of 70 patients under noradrenaline therapy, varied patterns of outcomes and results were noted. 34% were transferred to the ward, and 30% were also successfully discharged. The mortality rate of 25.1% shows that there is room for improvement in the treatment regimen. Although the dosing strategy in managing BP, MAP and HR were seen to be effective, there is room for development.</span></p> |
| title | Noradrenaline Utilisation and Hemodynamic Trends in Critically Ill Patients: An Observational Study from a Tertiary Care Hospital |
| topic | Noradrenaline, shock, critical care, vasopressor therapy, Mean arterial pressure |
| url | https://doi.org/10.5281/zenodo.18224340 |